Background: The relationship of marijuana use with coronary heart disease, including prognosis among patients with coronary heart disease, is uncertain.
Introduction
Marijuana use is not uncommon in the United States. A 2001-2002 national survey found that 4.1% of the adult population of the United States had used marijuana within the last year. [1] Although younger adults were most likely to report marijuana use, such use among adults aged 45 to 64 years was almost 3-fold higher than it had been a decade earlier.
Few studies have documented the long-term outcomes of marijuana users. In one previous study of marijuana use and mortality in the general population, [2] Sidney et al [2] found no increased risk of mortality associated with marijuana use among Kaiser Permanente enrollees less than 50 years old, very similar to earlier findings among Swedish conscripts. [3] However, marijuana use has cardiovascular effects that could pose particular risk for older adults and those with coronary heart disease, including a sizable increase in resting heart rate. [4] Moreover, in a previous analysis of the Onset Study, the risk of triggering a myocardial infarction (MI -heart attacks) was elevated almost 5-fold within 1 hour after smoking marijuana, compared with periods of nonuse, [5] consistent with case reports describing this phenomenon. [6] [7] [8] [9] [10] However, Steffens et al [11] recently found that orally administered delta9-tetrahydrocannabinol, a cannabinoid derivative, inhibits atherosclerosis progression in a mouse model, apparently through effects on lymphoid and myeloid cells. Marijuana use also has a wide variety of non-cardiovascular effects, including potentially adverse respiratory, neurologic, and immunologic effects. [12] [13] [14] The net balance of these apparently disparate effects of marijuana use on the most clinically vulnerable patients, such as those with established coronary heart disease, has not been studied. An impediment to understanding the clinical consequences of marijuana use has been the stark dearth of studies that have collected information on exposure. [2, 3, 15] To address this paucity of information, we explored the association of marijuana use assessed at the time of acute MI (AMI) with subsequent mortality among participants of the Onset Study. This multicenter, prospective cohort study included chart reviews and in-depth personal interviews with hospitalized patients with confirmed AMI. [16, 17] 
Discussion
In this preliminary prospective cohort study of early survivors of AMI (heart attacks), marijuana use, as measured at the time of hospitalization, was associated with 3-fold higher mortality after infarction. There was a gradient in risk, with the highest risk of death among individuals who used marijuana most frequently, and the risk was entirely unchanged by multivariate adjustment.
Marijuana use has important cardiovascular effects that could pose risk for patients with coronary heart disease. Among the best-defined of these is an increase in resting heart rate that can be selectively blocked by pretreatment with a cannabinoid receptor antagonist. [26] This effect may be related to the prolonged catecholamine release that marijuana can induce. [27] Marijuana use can also increase supine blood pressure, although it leads to orthostatic hypotension, postural dizziness, and even syncope (loss of consciousness) in some cases. [28, 29] At the same time that marijuana increases heart rate and, therefore, myocardial oxygen demand, it may also limit oxygen uptake. Marijuana smoking leads to a dose-dependent increase in carbon monoxide exposure [30] and even higher blood levels of carboxyhemoglobin than does cigarette smoking. [12] These effects have a demonstrably detrimental impact on patients with known coronary heart disease, in whom marijuana use decreases exercise time to the onset of angina by 50%, twice as great an effect as use of a standard cigarette. [31] Marijuana use could also lead to higher risk of death among patients by interfering with adherence to standard therapies. Although the relationship of marijuana use and adherence to therapy among patients with coronary heart disease has not been evaluated, it may interfere with adherence to other life-saving medication, such as antiretroviral therapy for human immunodeficiency virus infection. [32] The effects of marijuana use on cognitive function could conceivably exacerbate this further. [33] Over half of deaths among Onset Study participants who reported marijuana use were noncardiovascular, a substantially higher proportion than in nonusers. Despite the lack of specificity inherent in use of death certificates to assign accurate causes of death, [34] our results suggest that patients with coronary heart disease who use marijuana may be at particular for risk for all causes of death, and not recurrent cardiovascular disease alone. In this regard, the possible effects of marijuana use on unintentional injury and upper airway malignancy may be particularly important. [35, 36] Marijuana use also directly increases risk-taking behavior in some settings, [37, 38] but our findings were not altered by adjustment for other markers of risky behavior that were available, including binge drinking and cocaine use, perhaps because marijuana use was less strongly related to risk-taking in this relatively older aged cohort.
Similar to our findings, Sidney et al [2] also found that marijuana use was associated with AIDS-related death in men. It seems likely that this, at least in part, reflects confounding by indication, in which marijuana is used for nausea or appetite stimulation. However, cannabinoids may also have direct immunosuppressive effects that could accelerate disease progression among susceptible individuals. [14] Further studies to understand the degree to which marijuana use could influence post-infarct mortality (heart attack within 5-6 days after the first) via direct cardiovascular effects, cognitive changes that reduce adherence, noncardiovascular effects of marijuana, or simply other confounding factors related to marijuana use are clearly needed.
The Onset Study has both strengths and limitations. An important and perhaps unique strength is its assessment of marijuana use in a population of early survivors of MI; to our knowledge, no comparable cohort studies exist. All participants were interviewed in a standardized manner during hospitalization for enzymatically confirmed infarcts, and a relatively large body of information on clinical and sociodemographic variables was obtained.
As with any observational study, we cannot prove cause-and-effect relationships, although it is unclear how a randomized trial to test our findings could be performed. Our results were also consistently unchanged by adjustment for a wide variety of clinical characteristics, including alcohol intake and smoking. Nonetheless, there are apt to be unmeasured confounding clinical or lifestyle factors that may be responsible for our findings.
We asked participants to report their usual marijuana use over the year prior to the infarction that resulted in their hospitalization and did not have information on post-MI use, which is likely to have differed from that measured here. Assuming that some marijuana users cease use after hospitalization, we may have underestimated the true effect of post infarction marijuana use on survival. On the other hand, by assessing marijuana exposure before infarction and before follow-up, we minimized the potential bias that could affect assessment of post infarction marijuana use alone if sicker patients give up marijuana use more often than healthier patients after hospitalization. Future studies should also include repeated assessments of marijuana use to address this possibility.
In conclusion, marijuana use was associated with 3-fold greater mortality after AMI in this exploratory study, with a graded increase in risk with more frequent use. Because marijuana use appears to be increasing among middle-aged and older adults, this finding may have growing importance in the future. Although marijuana use does not appear to be associated with mortality among the general population, our results suggest that it may carry particular risks for vulnerable populations with established cardiovascular disease.
